Prothena Announces Phase 2 PASADENA Study Results to be Presented at International Congress of Parkinson’s Disease and Movement Disorders
05 août 2020 16h05 HE
|
Prothena Corporation plc
Phase 2 PASADENA Part 1 study results selected as an oral Top Abstract DUBLIN, Ireland, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with...
Prothena to Report Second Quarter 2020 Financial Results on August 6
30 juil. 2020 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, July 30, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeleine of investigational...
Prothena to Present at the Jefferies Virtual Healthcare Conference on June 3
27 mai 2020 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, May 27, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, today announced that members of...
Prothena Reports First Quarter 2020 Financial Results and Provides R&D Update and Updated Financial Guidance
06 mai 2020 16h05 HE
|
Prothena Corporation plc
Net cash used in operating and investing activities was $23.2 million in the first quarter; quarter-end cash and restricted cash position of $355.4 million provides funding to advance a broad pipeline...
Prothena to Report First Quarter 2020 Financial Results on May 6
29 avr. 2020 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, April 29, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, announced today that it will...
Prothena Provides Additional Information Regarding Upcoming Annual General Meeting of Shareholders in Response to COVID-19
24 avr. 2020 16h30 HE
|
Prothena Corporation plc
DUBLIN, Ireland, April 24, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA) today announced a change in the location of its annual general meeting of shareholder scheduled to be held...
Update on Phase 2 PASADENA Study of Prasinezumab (PRX002/RG7935) in Parkinson’s Disease
22 avr. 2020 09h15 HE
|
Prothena Corporation plc
DUBLIN, Ireland, April 22, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, announced that today Roche...
Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
03 avr. 2020 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, April 03, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, today announced that in...
Baseline Data from Phase 2 PASADENA Study of Prasinezumab (PRX002/RG7935) in Parkinson’s Disease to be Presented at AAT-AD/PD
31 mars 2020 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, March 31, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, today announced that baseline...
Prothena Announces Appointment of Brandon Smith as Chief Business Officer
03 mars 2020 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, March 03, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, today announced the...